EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cerus's Enterprise Value is $296.5 Mil.
Cerus's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-10.0 Mil. Therefore, Cerus's EV-to-EBIT for today is -29.55.
The historical rank and industry rank for Cerus's EV-to-EBIT or its related term are showing as below:
CERS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -34.64 Med: -13.3 Max: -3.1
Current: -29.55
During the past 13 years, the highest EV-to-EBIT of Cerus was -3.10. The lowest was -34.64. And the median was -13.30.
CERS's EV-to-EBIT is ranked worse than 100% of 459
companies
in the Medical Devices & Instruments industry
Industry Median: 20.2
vs CERS: -29.55
The historical data trend for Cerus's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cerus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cerus's EV-to-EBIT falls into.
Cerus's current Enterprise Value is $296.5 Mil.
Cerus's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (NAS:CERS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cerus's Enterprise Value for the quarter that ended in Mar. 2025 was $284.9 Mil.
Cerus's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Cerus's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CERS has been successfully added to your 